Plasma Levels of Soluble Tumor Necrosis Factor Receptor Type I During the Acute Phase Following Complicated Myocardial Infarction Predicts Survival in High-Risk Patients  by Ueland, Thor et al.
P
F
P
I
T
T
K
O
P
f
(
p
p
p
i
a
c
s
c
(
M
p
c
d
e
f
C
M
A
S
a
M
f
a
a
Journal of the American College of Cardiology Vol. 46, No. 11, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PAcute Myocardial Infarction
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OBJECTIVES We sought to determine the relationship between circulating cytokine levels and clinical
outcomes in patients with heart failure (HF) following acute myocardial infarction (AMI).
BACKGROUND Persistent inflammation plays a role in the development of HF, and various inflammatory
cytokines predict cardiovascular events in acute coronary syndromes.
METHODS We measured plasma levels of interleukin (IL)-6, monocyte chemotractant protein 1, IL-10, and
soluble tumor necrosis factor receptor type 1 (sTNFR1) during longitudinal testing over a period of two
years in 234 patients with HF following AMI recruited for participation in the OPTIMAAL trial,
focusing on the possible prognostic value of circulating cytokine levels in these patients.
RESULTS Measurement of sTNFR1 at baseline predicted all-cause mortality and cardiovascular death
in patients with post-MI HF after adjustment for other biomarkers that have been shown to
give prognostic information in HF patients, such as N-terminal B-type natriuretic peptide.
CONCLUSIONS Assessment of sTNFR1 levels might provide important prognostic information in patients
who develop HF during the acute phase following AMI. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.0392018–21) © 2005 by the American College of Cardiology Foundation
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iersistent inflammation plays a pathogenic role in heart
ailure (HF) (1,2). In particular, tumor necrosis factor
TNF)-alpha has been implicated as a mediator in this
rocess. Although several studies have focused on the
ossible role of TNF-alpha, the individual cytokine exists as
art of a cytokine network, and the effect of various
nflammatory cytokines is influenced by other inflammatory
s well as anti-inflammatory mediators, illustrating the
omplexity of this network (3). Thus, we and others have
uggested a pathogenic role for interleukin (IL)-6 and
hemokines such as monocyte chemoattractant peptide
MCP-1) in the development of myocardial failure (3).
oreover, anti-inflammatory cytokines such as IL-10 could
otentially have beneficial effects on cardiac remodeling (1,2).
Several studies have examined cytokine levels in HF during
ross-sectional testing, but few have reported these mediators
uring longitudinal follow-up, and the ability of these param-
ters to predict forthcoming clinical events is far from clear. To
urther elucidate the possible role of cytokines in HF, we
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ccepted August 1, 2005.herefore measured plasma levels of IL-6, MCP-1, IL-10, and
oluble TNF receptor type 1 (sTNFR1) as stable markers of
ctivity in the TNF system (4), during longitudinal testing in
atients with evidence of HF or left ventricular (LV) dysfunc-
ion following acute myocardial infarction (AMI), particularly
ocusing on the possible prognostic value of these cytokines.
ETHODS
tudy population. The design and main results of the OPtimal
rial In Myocardial infarction with Angiotensin II Antagonist
osartan (OPTIMAAL) have previously been reported in detail
5). Briefly, 5,477 patients with AMI complicated with HF
uring the acute phase were randomly assigned and titrated to a
arget dose of losartan (50 mg daily) or captopril (50 mg three
imes daily) as tolerated, and the patients were followed for a
edian 2.7 years for mortality and morbidity. The present study
as a prospectively designed sub-study of the main OPTIMAAL
rial comprising 234 consecutive patients from six centers that was
esigned to analyze plasma/serum levels of inflammatory/anti-
nflammatory mediators (6). For comparison, cytokine levels were
lso measured in 20 age- and gender-matched healthy controls.
iochemical analysis. Blood samples were obtained at
aseline and after one month, one year , and two years as
reviously described (6). Plasma concentrations of IL-6,
CP-1, IL-10, and sTNFR1 were quantified by enzyme
mmunoassays obtained from R&D Systems (Minneapolis,
innesota). N-terminal B-type natriuretic peptide (N-BNP)
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yzed as previously described (6).
tatistical methods. Differences between groups were
ompared by the Mann-Whitney U rank-sum test. Within
roups, differences were analyzed by the Wilcoxon rank-
um test. Relationships between variables were analyzed by
he Spearman rank test. Associations between cytokine
oncentrations and cardiovascular events (morbidity and
ortality) were analyzed by univariate analysis a priori and
hen by forced or forward conditional multivariate Cox
egression adjusting for predefined conventional predictors
smoking, previous MI, diabetes, medication, age, gender,
reatinine clearance, NYHA functional class, N-BNP, and
sCRP). Cardiovascular events (end points) were cardiovas-
ular death, total mortality, re-infarction, and angina.
aplan-Meier curves were generated, and the log rank test
as used to compare event rates in relation to cytokine levels
hen appropriate. Probability values are two sided, with
 0.05 being considered statistically significant.
ESULTS
irculating cytokine levels in post-MI HF patients. Base-
ine levels of IL-6, IL-10, MCP-1, and sTNFR1 were all
igher in our patients compared with healthy controls (Fig.
). Although these mediators markedly decreased during
ollow-up, circulating levels remained significantly increased
ompared with controls throughout the study. There was no
Abbreviations and Acronyms
AMI  acute myocardial infarction
HF  heart failure
hsCRP  high-sensitivity C-reactive protein
IL  interleukin
LV  left ventricular
MCP  monocyte chemoattractant peptide
N-BNP  N-terminal B-type natriuretic peptide
sTNFR1  soluble tumor necrosis factor receptor type 1
igure 1. Circulating levels of soluble tumor necrosis factor receptor type
(sTNFR1), interleukin (IL)-6, monocyte chemoattractant peptide
MCP)-1, and IL-10 in patients with acute myocardial infarction (AMI)
uring follow-up (mean  SEM). *p  0.001 vs. baseline (BL). Shadedt
rea represents 95% confidence interval for healthy age- and gender-
atched controls.ignificant difference in cytokines levels between the two
reatment groups, and the cytokine levels are presented as
ooled data from both groups (Fig. 1).
ssociations between cytokine levels and baseline clini-
al and biochemical variables. Several associations be-
ween baseline variables (Table 1) and cytokine levels were
evealed. First, high sTNF-R1 (p  0.01) and IL-6 (p 
.05) levels were observed in patients with clinical signs of
F (NYHA functional class II). Second, patients taking
iuretics had significantly higher levels of all cytokines,
atients taking beta-blockers had lower levels of IL-10 (p
.05) and sTNFR1 (p  0.001), and low sTNFR1 levels
ere also seen in subjects using statins (p  0.001) or
spirin (p  0.05). Third, a low creatinine clearance was
ssociated with high sTNFR1 levels (p  0.001) and both
TNFR1 (r 0.35; p 0.001) and IL-6 (r 0.29; p 0.001)
orrelated with age. Fourth, patients with a history of MI had
ower IL-10 levels (p  0.01). Finally, significant positive
elationships were found between N-BNP, hsCRP, and all
ytokines (except MCP-1 for hsCRP) (Fig. 2). In contrast to
hese correlations, there were no significant relationships be-
ween cytokine levels and LV ejection fraction.
ssociation between cytokine levels and clinical events. All
atients, regardless of treatment (losartan or captopril), were
ivided into two groups based on the median cytokine level
t baseline and at one month. Figure 3 shows the unadjusted
isk estimates in these groups in relation to clinical events.
ll-cause mortality was associated with high sTNFR1 levels
t baseline (1,981 pg/ml, risk ratio [RR] 7.1 [95%
onfidence interval (CI) 2.6 to 19.3]) and after one month
1,387 pg/ml, RR 6.2 [95% CI 1.7 to 21.8]) and high
L-6 levels at one month (3.0 pg/ml, RR 4.4 [95% CI 1.4
able 1. Baseline Characteristics of the Study Population
Demographics
229
ge (yrs) 68  10
ale, % 70
MI (kg/m2) 26.0  3.6
moking, % 68
istory
Hypertension, % 33
Previous myocardial infarction, % 11
Diabetes, % 11
edication
Diuretics, % 73
Beta-blocker, % 75
Statins, % 62
ASA, % 96
Warfarin, % 19
nterior, lateral infarct location, % 61
YHA functional class (I/II/III), % 36/49/14
reatinine clearance 85 ml/min, % 35
sCRP (mg/l) 70  65
-BNP (pmol/l) 1,361  725
ata are mean  SD.
ASA  acetylsalicylic acid; BMI  body mass index; hsCRP  high-sensitivity
-reactive protein; N-BNPN-terminal B-type natriuretic peptide; NYHANew
ork Heart Association.o 13.8]). Similarly, subjects dying from cause-specific
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Soluble TNF Receptor in Post-MI HF December 6, 2005:2018–21ardiovascular events had high sTNFR1 levels at baseline
RR 5.9 [95% CI 2.1 to 16.0]) and one month (RR 4.4
95% CI 1.2 to 16.2]). Recurrent nonfatal AMI during
ollow-up was associated with high IL-10 levels at one
onth (0.35 pg/ml, RR 2.7 [95% CI 1.2 to 6.0]). Finally,
he composite end point was associated with high levels of
TNFR1 at baseline (RR 2.9 [95% CI 1.6 to 5.3]) and one
onth (RR 2.5 [95% CI 1.3 to 5.1]) and high IL-10 levels
t one month (RR 2.0 [95% CI 1.0 to 3.9]).
ultivariate analysis. In a multivariate model, adjusting
or potential confounders (see Statistical methods), baseline,
ut not one-month, sTNFR1 levels were still associated
ith long-term all-cause mortality and cardiovascular death
Table 2). N-terminal B-type natriuretic peptide and
sCRP were also included in the multivariate model, but in
ontrast to sTNFR1 survival curves, the model showed no
igure 2. Correlations at baseline between circulating levels of high-
ensitivity C-reactive protein (hsCRP) and N-terminal B-type natriuretic
eptide (N-BNP) and sTNFR1, IL-6, MCP-1, and IL-10 in patients with
ost-myocardial infarction heart failure. Other abbreviations as in Figure 1.ignificant relationship with total mortality for baseline sevels of either hsCRP or N-BNP (Fig. 4). Interleukin-10
evels measured at one month remained a significant pre-
ictor of recurrent nonfatal AMI both in the forced (p 
.006; hazard ratio 3.3 [95% CI 1.4 to 7.5]) and stepwise (p
0.013; hazard ratio 2.7 [95% CI 1.2 to 5.8]) model.
imilar results were obtained for all calculations when
atients with diabetes were excluded.
TNFR1 levels during longitudinal follow-up in relation
o cardiovascular events. When comparing sTNFR1 in
urvivors with non-survivors, we found that the latter group
ad persistently higher levels at all time points during
ollow-up (Fig. 5). Furthermore, the prognostic value of
lasma sTNFR1 measurements in relation to all-cause
ortality remained significant at both one year (p  0.004;
R 2.1 [95% CI 1.8 to 2.5]) and two years (p  0.044; RR
.0 [95% CI 1.7 to 2.4]).
igure 3. Unadjusted risk ratios (RR) for sTNFR1, IL-6, MCP-1, and
L-10 at baseline (closed squares) and at one month (open squares) in
elation to incidence of total mortality (death), cardiac death (D), hospi-
alization for angina, reinfarctions (Reinf), and the composite end point.
ee text for cut-off values. Other abbreviations as in Figure 1.
able 2. Multivariate Models for sTNFR1 and All-Cause Mortality,
ardiac Death, and Composite End Point (All-Cause Mortality,
troke, or Nonfatal MI) During Follow-Up (Average 27 Months)
Baseline 1 Month
End-Point HR (95% CI) p Value HR (95% CI) p Value
ll-cause mortality
Forced 5.4 (1.5–20.3) 0.012 2.8 (0.7–10.6) 0.132
Stepwise 6.2 (1.9–20.7) 0.003 Excluded —
ardiac death
Forced 4.4 (1.3–16.9) 0.033 2.3 (0.6–9.1) 0.242
Stepwise 5.5 (1.6–18.3) 0.006 Excluded —
omposite end point
Forced 1.5 (0.8–2.9) 0.180 1.9 (0.9–3.8) 0.086
Stepwise Excluded — Excluded —
 test of trend.
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction;
TNFR1  soluble tumor necrosis factor receptor type 1.
DW
t
m
P
e
m
V
t
p
c
n
t
n
p
d
s
e
p
o
i
H
t
i
t
r
t
i
s
e
t
l
i
s
i
t
p
g
d
w
R
o
p
R
1
2
3
4
5
6
7
8
9
F
d
a
S
F
s

s
2021JACC Vol. 46, No. 11, 2005 Ueland et al.
December 6, 2005:2018–21 Soluble TNF Receptor in Post-MI HFISCUSSION
e have shown that high plasma levels of sTNFR1 during
he acute phase are associated with long-term all-cause
ortality and cardiovascular death in HF following AMI.
reviously, Rauchhaus et al. (7) reported that sTNF-R1
merged among all cytokine parameters as the strongest and
ost accurate prognostic marker in chronic HF. Recently,
algimigli et al. (8) reported that among several inflamma-
ory markers, sTNF-R1 remained the only independent
redictor of death and HF after MI. The present study
onfirms and extends these findings, evaluating the prog-
ostic significance of raised plasma sTNF-R1 in HF both in
he acute phase and during follow-up. In fact, we show that
on-survivors have raised plasma levels of sTNFR1 com-
ared with survivors not only at baseline but at all time points
igure 4. Kaplan-Meier curves showing the cumulative incidence of death
uring the entire study (median follow-up 27 months), according to high
nd low levels of sTNFR1 (A), hsCRP (B), and N-BNP (C) at baseline.
ee text for cut-off values. Abbreviations as in Figures 1 and 2.
igure 5. Circulating levels of sTNFR1 during two-year follow-up in
urvivors (solid squares) and non-survivors (open squares). *p 0.001; #p0.05; non-survivors vs. survivors. Four non-survivors died after the last
ampling (two years). Abbreviations as in Figure 1.uring the observation period. Importantly, we show that
TNF-R1 has predictive power independent of other well-
stablished risk markers such as N-BNP and hsCRP (9),
ossibly reflecting that we are focusing on a high-risk subgroup
f AMI patients that develop HF during the acute phase.
The lack of a relationship between sTNF-R1 and re-
nfarction in our study may be somewhat unexpected.
owever, TNF-alpha and sTNF-Rs may be released from
he failing myocardium, not only from inflamed tissue, and
t is possible that the high baseline levels of sTNFR1 in
hese patients with post-MI HF during the acute phase may
eflect the degree of myocardial damage and HF rather than
he degree of inflammation. Moreover, the marked decline
n cytokine levels after one month could reflect a more
teady state when the “cytokine storm” has settled. How-
ver, although there was an initial fall in sTNFR1 levels,
hese post-MI HF patients had markedly raised sTNFR1
evels compared with controls throughout the study, reflect-
ng an ongoing inflammation in these patients.
In the present study we show that plasma levels of
TNFR1 during the acute phase represent a strong and
ndependent predictor of all-cause and cardiovascular mor-
ality in post-MI HF patients. Although relatively few
atients were studied and although we had no placebo
roup, our findings suggest that assessment of sTNFR1
uring hospitalization may be useful in identifying patients
ho are at high risk of death following complicated MI.
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